Literature DB >> 16136965

[Expression of S100 protein in renal cell carcinoma and its relation with P53].

Jian-Fu Yang1, Xiang-Yang Zhang, Fan Qi.   

Abstract

OBJECTIVE: To investigate the expression of S100 in renal cell carcinoma (RCC) and its relation with P53.
METHODS: Immunohistochemical method was used to detect the expressions of S100A1, S100B and the mutant P53 in 36 RCC and 14 normal kidney tissues. The associations of S100 protein expression with the tumor pathological types, clinical stages and P53 expression were analyzed.
RESULTS: The positive rates of S100A1 expression in RCC and normal kidney tissues were 72.2% and 21.4%, respectively (P <0.01); S100A1 expression in RCC was significantly correlated with its stage and degree of malignancy. The positive rates of the mutant P53 expression in RCC and normal kidney tissues were 30. 6% and zero respectively (P <0.05), and its expression was not associated with the stage and degree of malignancy degree of RCC (P > 0.05). There was no significant difference in S100B expression between RCC (36.1%) and normal kidney tissues (64.3%, P >0.05). There was no significant correlation between the mutant P53 and S100A1 or S100B expression (P > 0.05).
CONCLUSION: S100A1 may serve as a new useful marker in judging the degree of malignancy and invasion of RCC.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 16136965

Source DB:  PubMed          Journal:  Zhong Nan Da Xue Xue Bao Yi Xue Ban        ISSN: 1672-7347


  3 in total

Review 1.  The evolution of S100B inhibitors for the treatment of malignant melanoma.

Authors:  Kira G Hartman; Laura E McKnight; Melissa A Liriano; David J Weber
Journal:  Future Med Chem       Date:  2013-01       Impact factor: 3.808

2.  Complex formation between S100B protein and the p90 ribosomal S6 kinase (RSK) in malignant melanoma is calcium-dependent and inhibits extracellular signal-regulated kinase (ERK)-mediated phosphorylation of RSK.

Authors:  Kira G Hartman; Michele I Vitolo; Adam D Pierce; Jennifer M Fox; Paul Shapiro; Stuart S Martin; Paul T Wilder; David J Weber
Journal:  J Biol Chem       Date:  2014-03-13       Impact factor: 5.157

3.  Prognostic value of [18F]-fluoro-deoxy-glucose PET/CT, S100 or MIA for assessment of cancer-associated mortality in patients with high risk melanoma.

Authors:  Markus Essler; Anna Link; Benedetta Belloni; Vesna Mirceva; Michael Souvatzoglou; Markus Thaler; Bernhard Haller; Ruediger Hein; Bernd J Krause
Journal:  PLoS One       Date:  2011-09-14       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.